These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 31430035)

  • 1. Liver stiffness measurement at complete virological response in hepatoma prediction for HBV-related cirrhosis patient with potent antiviral agent.
    Wang JH; Hu TH; Chen CH; Hung CH; Yen YH; Chang KC; Lu SN
    Kaohsiung J Med Sci; 2019 Nov; 35(11):708-714. PubMed ID: 31430035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B Virus Combo Mutations Improve the Prediction and Active Prophylaxis of Hepatocellular Carcinoma: A Clinic-Based Cohort Study.
    Yin J; Wang J; Pu R; Xin H; Li Z; Han X; Ding Y; Du Y; Liu W; Deng Y; Ji X; Wu M; Yu M; Zhang H; Wang H; Thompson TC; Ni W; Cao G
    Cancer Prev Res (Phila); 2015 Oct; 8(10):978-88. PubMed ID: 26290395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis.
    Jeon MY; Lee HW; Kim SU; Heo JY; Han S; Kim BK; Park JY; Kim DY; Ahn SH; Han KH
    Hepatol Int; 2017 May; 11(3):268-276. PubMed ID: 28224351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
    Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
    World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis B Virus (HBV) Core-Related Antigen During Nucleos(t)ide Analog Therapy Is Related to Intra-hepatic HBV Replication and Development of Hepatocellular Carcinoma.
    Honda M; Shirasaki T; Terashima T; Kawaguchi K; Nakamura M; Oishi N; Wang X; Shimakami T; Okada H; Arai K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Kaneko S
    J Infect Dis; 2016 Apr; 213(7):1096-106. PubMed ID: 26621908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Entecavir and Low Genetic Barrier Antiviral Agents for Hepatocellular Carcinoma in Hepatitis B Viral Cirrhosis: Propensity Score Matching.
    Li T; Qu Y; Wang Y; Lin C; Yang B; Wang L
    J Coll Physicians Surg Pak; 2019 Apr; 29(4):317-323. PubMed ID: 30925952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.
    Al-Hamoudi W; Elsiesy H; Bendahmash A; Al-Masri N; Ali S; Allam N; Al Sofayan M; Al Bahili H; Al Sebayel M; Broering D; Saab S; Abaalkhail F
    World J Gastroenterol; 2015 Jul; 21(26):8140-7. PubMed ID: 26185387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additional role of liver stiffness measurement in stratifying residual hepatocellular carcinoma risk predicted by serum biomarkers in chronic hepatitis B patients under antiviral therapy.
    Song BG; Sinn DH; Chi S; Kim K; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Eur J Gastroenterol Hepatol; 2018 Dec; 30(12):1447-1452. PubMed ID: 30063482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy.
    Lee HW; Yoo EJ; Kim BK; Kim SU; Park JY; Kim DY; Ahn SH; Han KH
    Am J Gastroenterol; 2014 Aug; 109(8):1241-9. PubMed ID: 24957159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of Liver Fibrosis after Long-Term Antiviral Therapy Assessed by Fibroscan in Chronic Hepatitis B Patients With Advanced Fibrosis.
    Chon YE; Park JY; Myoung SM; Jung KS; Kim BK; Kim SU; Kim DY; Ahn SH; Han KH
    Am J Gastroenterol; 2017 Jun; 112(6):882-891. PubMed ID: 28374814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognosis of hepatitis B-related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents.
    Kim CH; Um SH; Seo YS; Jung JY; Kim JD; Yim HJ; Keum B; Kim YS; Jeen YT; Lee HS; Chun HJ; Kim CD; Ryu HS
    J Gastroenterol Hepatol; 2012 Oct; 27(10):1589-95. PubMed ID: 22554121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis.
    Kim SS; Hwang JC; Lim SG; Ahn SJ; Cheong JY; Cho SW
    Am J Gastroenterol; 2014 Aug; 109(8):1223-33. PubMed ID: 24890440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants.
    Yang SC; Lee CM; Hu TH; Wang JH; Lu SN; Hung CH; Changchien CS; Chen CH
    J Antimicrob Chemother; 2013 Sep; 68(9):2154-63. PubMed ID: 23620466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced risk of hepatocellular carcinoma by achieving a subcirrhotic liver stiffness through antiviral agents in hepatitis B virus-related advanced fibrosis or cirrhosis.
    Kim BS; Seo YS; Kim YS; Lee CH; Lee HA; Um SH; Yoo JJ; Kim SG; Suh SJ; Jung YK; Ahn SH; Han KH; Yim HJ; Kim SU;
    J Gastroenterol Hepatol; 2018 Feb; 33(2):503-510. PubMed ID: 28666070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral drug resistance increases hepatocellular carcinoma: a prospective decompensated cirrhosis cohort study.
    Li L; Liu W; Chen YH; Fan CL; Dong PL; Wei FL; Li B; Chen DX; Ding HG
    World J Gastroenterol; 2013 Dec; 19(45):8373-81. PubMed ID: 24363530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy.
    Wang JH; Yen YH; Yao CC; Hung CH; Chen CH; Hu TH; Lee CM; Lu SN
    Liver Int; 2016 Dec; 36(12):1793-1799. PubMed ID: 27254286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On-treatment changes of liver stiffness at week 26 could predict 2-year clinical outcomes in HBV-related compensated cirrhosis.
    Wu S; Kong Y; Piao H; Jiang W; Xie W; Chen Y; Lu L; Ma A; Xie S; Ding H; Shang J; Zhang X; Feng B; Han T; Xu X; Huo L; Cheng J; Li H; Wu X; Zhou J; Sun Y; Ou X; Zhang H; You H; Jia J
    Liver Int; 2018 Jun; 38(6):1045-1054. PubMed ID: 29119705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status.
    Kim MN; Hwang SG; Kim BK; Park JY; Kim DY; Han KH; Kim SU; Ahn SH
    Gut Liver; 2019 Mar; 13(2):197-205. PubMed ID: 30602075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
    Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
    Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of chronic hepatitis B in severe liver disease.
    Fung J; Lai CL; Yuen MF
    World J Gastroenterol; 2014 Nov; 20(43):16053-61. PubMed ID: 25473157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.